Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Breast cancer mortality is primarily caused by recurrent tumors originating from residual cancer cells surviving therapy.
• Tumor recurrence after long remission periods suggests a dormant phase for some residual cancer cells.
• Mechanisms underlying breast cancer recurrence remain poorly understood.

Purpose of the Study:

• To investigate the role of Notch signaling in mammary tumor dormancy and recurrence.
• To identify therapeutic targets for preventing breast cancer relapse.

Main Methods:

• Utilized a mouse model of recurrent mammary tumorigenesis.
• Performed bioinformatics analyses on breast cancer patient data.
• Investigated Notch signaling activation and inhibition in tumor cells.
• Conducted meta-analysis of microarray data from over 4,000 breast cancer patients.

Main Results:

• Notch signaling is upregulated in tumor cells post-HER2/neu pathway inhibition.
• Activated Notch signaling persists in a subset of dormant residual tumor cells.
• Activation of Notch signaling accelerates tumor recurrence in mice.
• Inhibition of Notch signaling (genetic or pharmacological) reduces recurrence in mice.
• Elevated Notch pathway activity in patients correlates with increased recurrence rates.

Conclusions:

• Notch signaling plays a critical role in breast cancer recurrence from dormant residual tumor cells.
• Targeting Notch signaling during dormancy may offer a strategy to prevent breast cancer relapse.
• Tumor dormancy represents a targetable stage in breast cancer progression.